Market revenue in 2023 | USD 323.2 million |
Market revenue in 2030 | USD 505.2 million |
Growth rate | 6.6% (CAGR from 2023 to 2030) |
Largest segment | Inhaled |
Fastest growing segment | Other Allergens |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Inhaled, Drug, Other Allergens, Food |
Key market players worldwide | Rohm Co Ltd, Thermo Fisher Scientific Inc, PerkinElmer, BioMerieux SA, Siemens Healthineers AG ADR, Omega Healthcare Investors Inc, Danaher Corp, Alcon Inc, AbbVie Inc, Sanofi SA, Allergy Therapeutics PLC, Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, Sun Pharmaceutical Industries, Roche Holding AG, Merck & Co Inc, Astellas Pharma Inc, Epigenomics AG |
Inhaled was the largest segment with a revenue share of 55.07% in 2023. Horizon Databook has segmented the Saudi Arabia allergy diagnostics and therapeutics market based on inhaled, drug, other allergens, food covering the revenue growth of each sub-segment from 2018 to 2030.
The growth of this market can primarily be attributed to increasing involvement of the government and rising awareness about the benefits of noninvasive diagnostic procedures. In addition, rapid advancements in testing technologies are projected to fuel market growth in the region.
Over the years, there has been continuous government support to expand the healthcare sector in the country, which is expected to create new opportunities in the market. For instance, as per Vision 2030, the Saudi Arabian government plans to invest about USD 65 billion to advance the country’s healthcare infrastructure. Moreover, local as well as international market players are focusing on expanding their networks in Saudi Arabia.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account